From The Source

08 February 2024

Bioxyne subsidiary gets nod to manufacture cannabis, psilocybin and MDMA

1 minute read

Breathe Life Sciences wants to be the leading supplier to clinical trials and authorised prescribers by 2025.

This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.

End of content

No more pages to load

New Member Registration Existing member? log in.

You have selected the Trial membership level. change

This membership level is Free

Account Information

Email Address

Password

Confirm Password

First Name

Last Name

What part of the health sector do you work in?

Organisation

Job Title

AHPRA Number

Newsletter Frequency

Daily News

Full Name LEAVE THIS BLANK

Total to pay: Free

All payments subject to GST. If you are an international customer, contact us.

Processing... This can take up to 15 seconds.
You will be redirected once complete.

Bioxyne subsidiary gets nod to manufacture cannabis, psilocybin and MDMA

When will the real reforms be announced?

Healthscope tried to end Northern Beaches Hospital deal before

Quiet day on the health stump

COALITION COMMITS $7.6 MILLION TO POST-NATAL FAMILY SUPPORT IN THE TOP END

Tafe Directors Australia: DESIGN OF A NATIONAL REGISTRATION SCHEME FOR PERSONAL CARE WORKERS IN AGED CARE

Identity of rape-accused doctor revealed after court suppression order lifted

Pharmaceutical Benefits Scheme (PBS) Safety Net Threshold changes

Lumos secures further key US reimbursement milestones for FebriDX

Nyrada General Meeting Results

$1 million for new PET Scanner to transform cancer care

NDIS: APR release commitment

WHO Member States conclude negotiations and make significant progress on draft pandemic agreement

Research Australia’s Submission: Strategic Examination of R&D

DoHAC: Hearing Services Program statistics – Year to date 2024–25 to 31 March 2025

The Greens will finish the job of making IVF accessible to all who need it

2025 Ambulance Ramping Report Card: AMA President Dr Danielle McMullen on ABC News Breakfast

AMA: No end in sight to ambulance ramping at Australia’s logjammed hospitals

Clarity receives $11.1 million R&D Tax Incentive refund; Over $100 million in funding and refocus on high-priority programs

New Member Registration Existing member? log in.

Account Information

Payment Information We accept all major credit cards

Log in

New Member Registration Existing member? log in.

Account Information

Payment Information We accept all major credit cards